MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) announced that President and CEO Hyung Heon Kim will present a company overview at the H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025.

MetaVia also said CFO Marshall H. Woodworth will join one-on-one meetings with investors during the conference. Institutional investors registered for the event can request meetings via www.hcwevents.com. Investors wishing to meet outside the conference may contact Michael Miller at mmiller@rxir.com.

CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that President and Chief Executive Officer, Hyung Heon Kim,  will present a company overview at the H.C. Wainwright Liver Disease Virtual Conference taking place October 21-22, 2025.

Mr. Kim and Marshall H. Woodworth, Chief Financial Officer, will also participate in one-on-one meetings. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company.

To schedule a meeting with management outside of the conference, investors can contact Michael Miller at mmiller@rxir.com.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-present-at-the-hc-wainwright-liver-disease-virtual-conference-302582872.html

SOURCE MetaVia Inc.

FAQ

When will MetaVia (MTVA) present at the H.C. Wainwright Liver Disease Virtual Conference?

MetaVia will present on October 21-22, 2025 as part of the conference program.

Who from MetaVia will present and meet investors at the conference?

President and CEO Hyung Heon Kim will present; CFO Marshall H. Woodworth will participate in one-on-one meetings.

How can institutional investors request a meeting with MetaVia (MTVA) at the conference?

Registered institutional investors can request meetings by logging into www.hcwevents.com.

How do investors schedule a meeting with MetaVia management outside the conference?

Investors can contact Michael Miller at mmiller@rxir.com to arrange meetings outside the conference.

What topics will MetaVia cover in the company overview at the October 2025 conference?

The announcement states the presentation is a company overview; no additional topics or slides were specified.